Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors

被引：2
|
作者：
Janku, Filip [1 ]
Birrer, Michael [2 ]
Richardson, Debra [3 ]
Chu, Christina [4 ]
Goel, Sanjay [5 ]
Su, Ying [6 ]
Matin, Bahar [6 ]
Kuida, Keisuke [6 ]
Ruiz-Soto, Rodrigo [6 ]
Hamilton, Erika Paige [7 ,8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA
[4] Fox Chase Canc Ctr, Havertown, PA USA
[5] Albert Einstein Coll Med, Bronx, NY 10467 USA
[6] Deciphera Pharmaceut LLC, Waltham, MA USA
[7] Sarah Cannon Res Inst, Nashville, TN USA
[8] Tennessee Oncol PLLC, Nashville, TN USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [41] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika Paige
    Chu, Christina
    Richardson, Debra L.
    Arend, Rebecca Christian
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Hays, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [43] A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations
    Tolcher, Anthony W.
    Hong, David S.
    Vandross, Andrae Lavon
    Psoinos, Charles M.
    Brennan, Denise Marie
    Sherman, Matthew L.
    Ruiz-Soto, Rodrigo
    Reu, Frederic J.
    Weekes, Colin D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
    C. Massard
    P. A. Cassier
    A. Azaro
    B. Anderson
    E. Yuen
    D. Yu
    G. Oakley
    K. A. Benhadji
    S. Pant
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 335 - 344
  • [45] A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
    Massard, C.
    Cassier, P. A.
    Azaro, A.
    Anderson, B.
    Yuen, E.
    Yu, D.
    Oakley, G., III
    Benhadji, K. A.
    Pant, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 335 - 344
  • [46] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [47] Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors
    Abu-Khalaf, Maysa M.
    Baumgart, Megan A.
    Gettinger, Scott N.
    Doddamane, Indukala
    Tuck, David P.
    Hou, Shihe
    Chen, Nianhang
    Sullivan, Catherine
    Lezon-Geyda, Kimberly
    Zelterman, Daniel
    Hatzis, Christos
    Deshpande, Hari
    Digiovanna, Michael P.
    Azodi, Masoud
    Schwartz, Peter E.
    Harris, Lyndsay N.
    CANCER, 2015, 121 (11) : 1817 - 1826
  • [48] Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
    Dumbrava, Ecaterina Elena
    Shapiro, Geoffrey
    Bendell, Johanna C.
    Yap, Timothy A.
    Jeselsohn, Rinath
    Lepley, Denise M.
    Hurley, Sabrina
    Lin, Kevin K.
    Liao, Michelle
    Habeck, Jenn
    Enke, Aaron
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] A PHASE 1B/2A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Jaraczewska-Baumann, M.
    Korkosz, M.
    Sulyok, G.
    Sramek, P.
    Rojkovich, B.
    Daniluk, S.
    Bartalos, J.
    Zack, D. J.
    Foster, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 481 - 481
  • [50] Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
    Carneiro, Benedito A.
    Jotte, Robert M.
    Gabrail, Nashat Y.
    Wentzel, Kristopher
    Huang, Funan
    Chaturvedi, Shalini
    Weispfenning, Anke
    Hiemeyer, Florian
    Morcos, Peter N.
    Soler, Lidia Mongay
    Childs, Barrett H.
    Hansen, Aaron R.
    CANCER RESEARCH COMMUNICATIONS, 2025, 5 (03): : 444 - 457
12345